BELLUS Health Stock Forecast, Price & News

+0.19 (+4.33 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $4.58
50-Day Range
MA: $3.78
52-Week Range
Now: $4.58
Volume503,259 shs
Average Volume39,610 shs
Market Capitalization$728.76 million
P/E RatioN/A
Dividend YieldN/A
BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A



Sales & Book Value

Annual Sales$30,000.00
Price / Sales24,291.86
Book Value$0.25 per share


Net Income$-7,010,000.00
Net Margins-49,910.34%


Market Cap$728.76 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.50 out of 5 stars

Medical Sector

1584th out of 2,024 stocks

Pharmaceutical Preparations Industry

668th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.19 (+4.33 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLUSF News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUSF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BELLUS Health (OTCMKTS:BLUSF) Frequently Asked Questions

What stocks does MarketBeat like better than BELLUS Health?

Wall Street analysts have given BELLUS Health a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BELLUS Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (OTCMKTS:BLUSF) issued its earnings results on Wednesday, May, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The firm earned $0.01 million during the quarter. BELLUS Health had a negative net margin of 49,910.34% and a negative trailing twelve-month return on equity of 48.37%.
View BELLUS Health's earnings history

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:
  • Roberto Bellini, President, Chief Executive Officer & Director
  • François Desjardins, Vice President-Finance
  • Denis Garceau, Senior Vice President-Drug Development
  • Tony Matzouranis, Vice President-Business Development
  • Sébastien Roy, Secretary

Who are some of BELLUS Health's key competitors?

What is BELLUS Health's stock symbol?

BELLUS Health trades on the OTCMKTS under the ticker symbol "BLUSF."

How do I buy shares of BELLUS Health?

Shares of BLUSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLUSF stock can currently be purchased for approximately $4.58.

How much money does BELLUS Health make?

BELLUS Health has a market capitalization of $728.76 million and generates $30,000.00 in revenue each year.

How many employees does BELLUS Health have?

BELLUS Health employs 10 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

Where are BELLUS Health's headquarters?

BELLUS Health is headquartered at 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company can be reached via phone at 45-0680-4500 or via email at [email protected]

This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.